思力华能倍乐的价格多少钱

At present, bronchodilators have become the core drugs for the treatment of stable COPD. The existing long-acting inhaled bronchodilators include anticholinergics and β2 receptor agonists. It is a classic drug for the treatment of stable COPD. On this basis, Boehringer Ingelheim has specially developed a new high-efficiency inhaled long-acting β2 receptor agonist olodaterol. The two work together to synergize (it takes effect within 5 minutes after taking the drug, improves lung function, and the effect lasts for 24 hours).

So how much does Siberia Respimat cost? According to the editor's understanding, due to the floating exchange rate and the price is not fixed, please consult Medical Companion Travel for specific prices.

Sliva Respimat can significantly improve patients' lung function, reduce symptoms of COPD, improve quality of life, and can effectively reduce the incidence of acute exacerbations. In addition, its original soft mist inhalation device Slivar Respimat realizes active spraying, which is easy for patients to inhale, ensuring efficient lung deposition, which is conducive to ensuring the clinical efficacy of the drug.

Slivar Respimat is a bronchodilator (long-acting anticholinergic drug) whose main ingredient is tiotropium bromide. There are two dosage forms on the market: tiotropium bromide powder inhalation and tiotropium bromide spray. Tiotropium bromide is the first long-acting anticholinergic drug (LAMA) with a drug effect that lasts for 24 hours. It was launched globally in 2002 and entered China in 2006. It has played an important role in the treatment of COPD for ten years. Slivar Respimat is suitable for the maintenance treatment of chronic obstructive pulmonary disease, including chronic bronchitis and emphysema, the maintenance treatment of dyspnea and the prevention of acute exacerbations. This type of drug has a synergistic and complementary effect when combined with β2 receptor agonists; anticholinergic drugs have a slow peak time and cannot be used alone to treat acute severe asthma or COPD.

Inhalants disperse drug particles through the kinetic energy of the user's active inhalation of air. Therefore, the flow rate of dry powder mist particles matches the user's inhalation flow rate, which means it is related to the patient's inhalation flow rate. If the patient's condition is severe and unable to produce a certain inspiratory flow rate, the inhalation efficiency of the drug may be reduced and the drug efficacy will be unsatisfactory. In this case, it may be considered under the advice of a doctor.

Recommended related hot articles: /newsDetail/82279.html